Aura Biosciences, Inc. $AURA Shares Bought by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. grew its position in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 39.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,100,000 shares of the company's stock after purchasing an additional 2,000,000 shares during the quarter. Aura Biosciences makes up about 1.1% of Frazier Life Sciences Management L.P.'s holdings, making the stock its 18th largest position. Frazier Life Sciences Management L.P. owned 6.85% of Aura Biosciences worth $50,410,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Montanova Capital LLC boosted its position in shares of Aura Biosciences by 64.8% in the 2nd quarter. Montanova Capital LLC now owns 7,206,217 shares of the company's stock valued at $51,164,000 after purchasing an additional 2,833,333 shares during the period. BlackRock Inc. acquired a new position in Aura Biosciences during the second quarter worth approximately $33,424,000. Nantahala Capital Management LLC purchased a new stake in Aura Biosciences in the second quarter valued at approximately $20,952,313. Vanguard Group Inc. boosted its holdings in shares of Aura Biosciences by 16.7% in the third quarter. Vanguard Group Inc. now owns 2,890,503 shares of the company's stock valued at $17,863,000 after acquiring an additional 413,001 shares during the period. Finally, Jupiter Topco LLC purchased a new position in shares of Aura Biosciences during the second quarter worth approximately $17,788,000. Institutional investors and hedge funds own 96.75% of the company's stock.

Insiders Place Their Bets

In other news, insider Anthony Gibney sold 12,824 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $6.42, for a total transaction of $82,330.08. Following the completion of the transaction, the insider directly owned 265,354 shares of the company's stock, valued at approximately $1,703,572.68. This represents a 4.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 1.90% of the company's stock.

Analyst Upgrades and Downgrades

AURA has been the subject of several research reports. Wall Street Zen downgraded shares of Aura Biosciences from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Leerink Partners set a $17.00 target price on shares of Aura Biosciences in a report on Tuesday, May 12th. HC Wainwright decreased their target price on shares of Aura Biosciences from $24.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, August 11th. Finally, Weiss Ratings upgraded Aura Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 14th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Aura Biosciences currently has an average rating of "Hold" and an average price target of $17.50.

Aura Biosciences Stock Performance

Shares of Aura Biosciences stock opened at $7.56 on Monday. Aura Biosciences, Inc. has a one year low of $4.73 and a one year high of $9.53. The company has a market cap of $784.05 million, a P/E ratio of -4.32 and a beta of 0.40. The firm has a fifty day moving average of $7.35 and a two-hundred day moving average of $6.97.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.10). As a group, equities analysts predict that Aura Biosciences, Inc. will post -1.61 earnings per share for the current year.

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.

Want to see what other hedge funds are holding AURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aura Biosciences, Inc. (NASDAQ:AURA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source